Publisher: Renub Research Published: June 2010

Report Details
Global Diabetes Market Trends & Future Forecast Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1 report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering: Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence Region wise Diabetes Health Expenditure and Mortality Top 10 Countries Diabetes Population and Future Forecast Top 5 Countries Diabetes Drug Market and Future Forecast Top 7 Countries Insulin Market and Future Forecast Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market

Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market
Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market

Research Highlights
USA controls more than 50% of the total Diabetes Drug market share in 2009 Global Insulin Market is estimated to reach around US$ 17 Billion by 2013 China will have the second highest Insulin market share by 2012 replacing Germany DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015 GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015 Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.

Renub Research

Page 2 of 18

Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030. Januvia is proving a blockbuster of DPP IV Inhibitors segment expected to be more than US$ 4 Billion by 2017 Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009 Japan Insulin market is expected to be more than US$ 1 Billion by 2010

Key Drugs Analyzed Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus, GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide Data Sources Information and data in this report has been collected from various printable and nonprintable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.

Renub Research

Page 3 of 18

Published By

Renub Research
A116B, Sector27 Noida 201301 Phone: +91-120-421-9822, 424-9780 (India) +1-678-302-0700 (US) Email: info@renub.com www.renub.com

Global Diabetes Market Trends & Future Forecast Diabetes Drug (Anti-Diabetic Drug), Insulin, DPPIV, GLP-1 Renub Research, 2010 Edition 1.0 All rights reserved. This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic mechanical, photocopying, recording or otherwise without the prior written permission of the publishers.

Renub Research

Page 4 of 18

Table of Contents
1. 2. Executive Summary Global Diabetes Market 2.1 2.2 2.3 2.4 Global Diabetes Drug Market & Future Forecast Global Insulin Market & Future Forecast Global Diabetes Drug Market Share & Future Forecast of (Brazil, China, Japan, USA, India) Global Insulin Market Share & Future Forecast of (Mexico, Germany, Russia, China, Japan,

USA, India) 2.5 2.6 3. Global Dipeptidyl Peptidase (DPP IV) Inhibitors Market & Future Forecast Global Glucagon-like Peptide-1(GLP-1) Market & Future Forecast

Global Top 6 Diabetes Drug Brands Market Performance 3.1 3.2 3.3 3.4 3.5 3.6 Avandia Past & Present Market Actos Past, Present & Future Forecast Amaryl Past, Present & Future Forecast Avandamet Past, Present & Future Forecast Prandin/Novonorm Past & Present Market Starlix Past, Present & Future Forecast

4.

Global Top 9 Insulin Brands Market Performance 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 Novomix Past, Present & Future Forecast Novorapid Past, Present & Future Forecast Levemir Past, Present & Future Forecast Degludec Yet to be Launched - Future Forecast Degludecplus Yet to be Launched Future Forecast Humalog Past & Present Market Humulin Past & Present Market Apidra Past, Present & Future Forecast Lantus Past, Present & Future Forecast

Renub Research

Page 5 of 18

5.

Global DPP-IV Inhibitors Brands Market Performance 5.1 5.2 5.3 5.4 5.5 Januvia Past, Present & Future Forecast Onglyza Past, Present & Future Forecast Alogliptin Yet to be Launched Future Forecast Galvus Past, Present & Future Forecast DPP-IV Inhibitors In Trial Phases

6.

Global GLP-1 Agonists Brands Market Performance 6.1 6.2 6.3 6.4 6.5 Byetta Past, Present & Future Forecast Victoza Past, Present & Future Forecast Exenatide LAR Yet to be Launched Future Forecast Syncria Yet to be Launched Future Forecast Taspoglutide Yet to be Launched Future Forecast

7.

Regional Estimates for Diabetes 7.1 7.2 7.3 7.4 Diabetes Population & Prevalence Impaired Glucose Tolerance (IGT) Population & Prevalence Mortality Due to Diabetes North America & Caribbean Region Diabetes & Impaired Glucose Tolerance (IGT) Population & Prevalence Healthcare Expenditure & Type 1 Diabetes Mortality

7.4.1 7.4.2 7.4.3 7.5

Middle East and North African Region Diabetes & Impaired Glucose Tolerance (IGT) Population & Prevalence Healthcare Expenditure & Type 1 Diabetes Mortality

7.5.1 7.5.2 7.5.3 7.6

South-East Asian Region Diabetes & Impaired Glucose Tolerance (IGT) Population & Prevalence Healthcare Expenditure & Type 1 Diabetes Mortality

7.6.1 7.6.2 7.6.3 7.7

European Region Diabetes & Impaired Glucose Tolerance (IGT) Population & Prevalence Healthcare Expenditures & Type 1 Diabetes Page 6 of 18

7.7.1 7.7.2

Renub Research

7.7.3 7.8

Mortality

South and Central American Region Diabetes & Impaired Glucose Tolerance (IGT) Population & Prevalence Healthcare Expenditures & Type 1 Diabetes Mortality

7.8.1 7.8.2 7.8.3 7.9

Western Pacific Region Diabetes & Impaired Glucose Tolerance (IGT) Population & Prevalence Healthcare Expenditures & Type 1 Diabetes Mortality

7.9.1 7.9.2 7.9.3 7.10

African Region Diabetes & Impaired Glucose Tolerance (IGT) Population & Prevalence Healthcare Expenditure & Type 1 Diabetes Mortality

7.10.1 7.10.2 7.10.3 8.

Global Top 10 Diabetic Countries Performance 8.1 8.2 8.3 Number of People in Top 10 Diabetic Place Prevalence of Diabetes in Top 10 Countries India Diabetes Population & Future Scenario India Diabetes Drug Market & Future Forecast India-Insulin Market & Future Forecast

8.3.1 8.3.2 8.3.3 8.4

China Diabetes Population & Future Scenario Diabetes Drug Market & Future Forecast China Insulin Market & Future Forecast

8.4.1 8.4.2 8.4.3 8.5

United States Diabetes Population & Future Scenario Diabetes Drug Market & Future Forecast Insulin Market & Future Forecast

8.5.1 8.5.2 8.5.3 8.6

Brazil Diabetes Population & Future Scenario Diabetes Drug Market & Future Forecast

8.6.1 8.6.2 8.7

Russia Diabetes Population & Future Scenario Insulin Market & Future Forecast Page 7 of 18

8.7.1 8.7.2

Renub Research

8.8

Japan Diabetes Population & Future Scenario Diabetes Drug Market & Future Forecast Insulin Market & Future Forecast

8.8.1 8.8.2 8.8.3 8.9

Germany Diabetes Population & Future Scenario Insulin Market & Future Forecast

8.9.1 8.9.2 8.10

Mexico Diabetes Population & Future Scenario Insulin Market & Future Forecast

8.10.1 8.10.2 8.11

Indonesia Diabetes Population & Future Scenario

8.11.1 8.12

Pakistan Diabetes Population & Future Scenario

8.12.1

Renub Research

Page 8 of 18

List of Figures:
Figure 2-1: Global Diabetes Drug Market (Billion US$), 2005 2009 Figure 2-2: Global Forecast of Diabetes Drug Market (Billion US$), 2010 2013 Figure 2-3: Global Insulin Market (Billion US$), 2004 2009 Figure 2-4: Global Forecast of Insulin Market (Billion US$), 2010 2013 Figure 2-5: Global Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2007 2009 Figure 2-6: Global Forecast of Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2010 2013 Figure 2-7: Global Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India) (Percent), 2007 2009 Figure 2-8: Global Forecast for Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India) (Percent), 2010 2013 Figure 2-9: Global DPP IV Inhibitors Market (Million US$), 2009 2015 Figure 2-10: Global GLP-1 Market (Million US$), 2009 2015 Figure 3-1: Global Avandia Diabetes Drug Brand Sales (Million US$), 2004 2009 Figure 3-2: Global Actos Diabetes Drug Sales (Billion US$), 2005 2009 Figure 3-3: Global Forecast for Actos Diabetes Drug Sales (Billion US$), 2010 & 2013 Figure 3-4: Global Amaryl Diabetes Drug Sales (Million US$), 2006, 2007, 2009, & Q1 2010 Figure 3-5: Global Forecast for Amaryl Diabetes Drug Sales (Million US$), 2010 2012 Figure 3-6: Global Avandamet Diabetes Drug Sales (Million US$), 2006 2009 Figure 3-7: Global Forecast for Avandamet Diabetes Drug Sales (Million US$), 2010 2012 Figure 3-8: Global Prandin/Novonorm Diabetes Drug Sales (Million US$), 2007 2009 Figure 3-9: Global Starlix Diabetes Drug Sales (Million US$), 2007 2009E Figure 3-10: Global Forecast for Starlix Diabetes Drug Sales (Million US$), 2010 2012 Figure 4-1: Global NovoMix Insulin Sales (Million US$), 2005 2009 Figure 4-2: Global NovoRapid Insulin Sales (Million US$), 2005 2009 Figure 4-3: Global Levemir Insulin Sales (Million US$), 2005 2009 Figure 4-4: Global Humalog Insulin Sales (Million US$), 2006 2009 Figure 4-5: Global Humulin Insulin Brand Sales (Million US$), 2006 2009 Figure 4-6: Global Apidra Insulin Sales (Million US$), 2005 2009, Q1 2010 Figure 4-7: Apidra Forecast for Insulin Sales (Million US$), 2009 2013 Figure 4-8: Global Lantus Insulin Sales (Million US$), 2006 2009, Q1 2010 Figure 4-9: Global Forecast for Lantus Insulin Sales (Million US$), 2010 2015 Figure 5-1: Global Januvia DPP-IV Inhibitors Sales (Million US$), 2007 2009 Figure 5-2: Global Forecast for Januvia DPP-IV Inhibitors Sales (Million US$), 2010 2017

Renub Research

Page 9 of 18

Figure 5-3: Global Onglyza DPP-IV Inhibitors Sales & Future Forecast (Million US$), 2009 2017 Figure 5-4: Global Future Forecast for Alogliptin DPP-IV Inhibitors Sale (Million US$), 2011 2017 Figure 5-5: Global Galvus DPP-IV Inhibitors Sale (Million US$), 2007 2009 Figure 5-6: Global Future Forecast for Galvus DPP-IV Inhibitors Sale (Million US$), 2010 2012 Figure 6-1: Global Byetta GLP-1 Sales (Million US$), 2006 2009 Figure 6-2: Global Forecast for Byetta GLP-1 Sales (Million US$), 2010 2017 Figure 6-3: Global Victoza GLP-1 Sales & Future Forecast (Million US$), 2009 2017 Figure 6-4: Global Forecast for Exenatide LAR GLP-1 Sales (Million US$), 2011 2017 Figure 6-5: Global Forecast for Syncria GLP-1 Sales (Million US$), 2013 2017 Figure 6-6: Global Forecast for Taspoglutide GLP-1 Sales (Million US$), 2012 2017 Figure 8-1: India Number of People with Diabetes (Million), 2003, 2007, 2010 Figure 8-2: India Diabetes Drug Market (Billion INR), 2006 2009 Figure 8-3: India Forecast for Diabetes Drug Market (Billion INR), 2010 2014 Figure 8-4: India Share of Human Insulin Market, Animal Insulin Market & Oral Diabetes Market (in Percent), 2003 & 2007 Figure 8-5: India Insulin Market (Million INR), 2006 2009 Figure 8-6: India Forecast for Insulin Market (Million INR), 2010 2014 Figure 8-7: China Number of Diabetes Patients (Million), 2003, 2007 & 2010 Figure 8-8: China Diabetes Drug Market (Billion Yuan), 2006 2009E Figure 8-9: China Forecast for Diabetes Drug Market (Billion Yuan) 2010 2014 Figure 8-10: China Insulin Market (Million Yuan), 2007 2009 Figure 8-11: China Forecast for Insulin Market (Million Yuan), 2010 2014 Figure 8-12: USA Number of Diabetes Patients (Million), 2003, 2006, 2007 & 2010 Figure 8-13: USA Diabetes Drug Market (Million US$), 2002 2009 Figure 8-14: USA Forecast for Diabetes Drug Market (Million US$), 2010 2014 Figure 8-15: USA Insulin Market (Billion US$), 2003 2009 Figure 8-16: USA Forecast for Insulin Market (Billion US$), 2010 2014 Figure 8-17: Brazil Diabetes Population (Million), 2003, 2007 & 2010 Figure 8-18: Brazil Diabetes Drug Market (Million US$), 2008 2013 Figure 8-19: Russia Number of Diabetes Population (Million), 2005 & 2010 Figure 8-20: Russia Insulin Market (Million US$), 2002, 2005 2009 Figure 8-21: Russia Forecast for Insulin Market (Million US$), 2010 2014 Figure 8-22: Japan Number of Diabetes Population (Million), 2003 2010 Figure 8-23: Japan Diabetes Drug Market (Million US$), 2002 2009 Figure 8-24: Japan Forecast for Diabetes Market (Million US$), 2010 2014 Figure 8-25: Japan Insulin Market (Million US$), 1998 2009 Figure 8-26: Japan Forecast for Insulin Market (Million US$), 2010 2014

Renub Research

Page 10 of 18

Figure 8-27: Germany Number of Diabetes Patients (Million), 2003 2010 Figure 8-28: Germany Insulin Market (Million US$), 2004 2009E Figure 8-29: Germany Forecast for Insulin Market (Billion US$), 2010 2014 Figure 8-30: Mexico Number of People with Diabetes (Million), 2003 2005, 2007 & 2010 Figure 8-31: Mexico Insulin Market (Million US$), 2004 2009E Figure 8-32: Mexico Forecast for Insulin Market (Million US$), 2010 2014 Figure 8-33: Pakistan Number of Diabetes Patients (Million), 2003, 2007 & 2010

Renub Research

Page 11 of 18

List of Tables:
Table 4-1: Novomix Forecast for Insulin Sales (Million US$), 2010 2030 Table 4-2: Global Forecast for NovoRapid Insulin Sales (Million US$), 2010 2030 Table 4-3: Global Forecast for Levemir Insulin Sales (Million US$), 2010 2030 Table 4-4: Degludec Forecast for Insulin Sales (Million US$), 2010 2030 Table 4-5: DegludecPlus Forecast for Insulin Sales (Million US$), 2010 2030 Table 5-1: DPP-4 Inhibitors In Trial Phase Table 7-1: Regional Estimates for (Number of People with Diabetes, Comparative Diabetes Prevalence %) (20-79 years), 2010 and 2030 Table 7-2: Regional Estimates for (Number of People with IGT, Comparative IGT Prevalence %) (20-79 years), 2010 and 2030 Table 7-3: Regional Diabetes Mortality (20-79 Years; Thousand), 2010 Table 7-4: North America and Caribbean Region Population & Adult Population (Million), 2010 & 2030 Table 7-5: North America and Caribbean Region Number of People with Diabetes & Comparative Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030 Table 7-6: North America and Caribbean Region Number of People with IGT & Comparative Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030 Table 7-7: North America and Caribbean Region Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030 Table 7-8: North America and Caribbean Region Diabetes Mortality (20-79 Years; Thousand), 2010 Table 7-9: Middle East and North African Region Population & Adult Population (Million), 2010 & 2030 Table 7-10: Middle East and North African Region Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030 Table 7-11: Middle East and North African Region Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030 Table 7-12: Middle East and North African Region Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030 Table 7-13: Middle East and North African Region Diabetes Mortality (20-79 Years; Thousand), 2010 Table 7-14: South-East Asian Region Population & Adult Population (Million), 2010 & 2030 Table 7-15: South-East Asian Region Number of People with Diabetes & Comparative Prevalence (2079 Years; Million, Percent), 2010 & 2030 Table 7-16: South-East Asian Region Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030 Table 7-17: South-East Asian Region Diabetes Mortality (20-79 Years; Thousand), 2010 Table 7-18: European Region Population & Adult Population (Million), 2010 & 2030

Renub Research

Page 12 of 18

Table 7-19: European Region Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million Percent), 2010 & 2030 Table 7-20: European Region Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030 Table 7-21: European Region Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030 Table 7-22: European Region Diabetes Mortality (20-79 Years; Thousand), 2010 Table 7-23: South and Central American Region Population & Adult Population (Million), 2010 & 2030 Table 7-24: South and Central American Region Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030 Table 7-25: South and Central American Region Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030 Table 7-26: South and Central American Region Diabetes Mortality (20-79 Years; Thousand), 2010 Table 7-27: Western Pacific Region Population & Adult Population (Million), 2010 & 2030 Table 7-28: Western Pacific Region Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030 Table 7-29: Western Pacific Region Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030 Table 7-30: Western Pacific Region Diabetes Mortality (20-79 Years; Thousand), 2010 Table 7-31: African Region Population & Adult Population (Million), 2010 & 2030 Table 7-32: African Region Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030 Table 7-33: African Region Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030 Table 7-34: African Region Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030 Table 7-35: African Region Diabetes Mortality (20-79 Years; Thousand), 2010 Table 8-1: Global Top 10 Countries Number of People with Diabetes (20-79 age group) (Million) 2010 & 2030 Table 8-2: Global Top 10 Countries in Prevalence of Diabetes (20-79 age group) (Percent), 2010 & 2030 Table 8-3: India Forecast for Number of People with Diabetes (Million), 2011 2030 Table 8-4: China Forecast for Number of Diabetes Patients (Million), 2011 2030 Table 8-5: USA Forecast for Number of Diabetes Patients (Million), 2011 2030 Table 8-6: Brazil Forecast for Number of Diabetes Population (Million), 2011 2030 Table 8-7: Russia Forecast for Number of Diabetes Population (Million), 2011 2030 Table 8-8: Mexico Forecast for Number of Diabetes Patients (Million), 2011 2030

Renub Research

Page 13 of 18

Table 8-9: Indonesia Forecast for Number of Diabetes Patients (Million), 2010 2030 Table 8-10: Pakistan Forecast for Number of Diabetes Patients (Million), 2011 2030

Renub Research

Page 14 of 18

Order Form
Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780 Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to info@renub.com

Format
Report Title: Global Diabetes Market Trends & Future Forecast Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

Single User (Email from Publisher) US$ 1,100

Hard Copy (Mail Delivery) US$ 1,250

CD Rom (Mail Delivery) US$ 1,250

Global Site License (Multiple User License) US$ 1,600

For ordering this report: Three easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.): http://renub.com/reports/showdetails.aspx?id=27 2) Order by Wire Transfer: http://renub.com/reports/wiretransfer.aspx?id=27&pid=1089 To pay by Wire Transfer, please, fill in your contact details in the form below:

Renub Research

Page 15 of 18

Bank Details
Account Name: Renub Research A/C No.: 109102000023296 Name of Bank: IDBI Bank Ltd. Swift Code: IBKLINBB010 Bank Address: 4th Floor Indian Red Cross Building 1 Red Cross Road Opposite Parliament Street New Delhi 110001 India

Contact Information
First Name: Email: Job Title: Company: Address: City: Postal/Zip Code: Country: Phone: Mobile: Fax: Report Format: Your message: Last Name:

Renub Research

Page 16 of 18

3) Order by Check Please post the check accompanied by this form, to: Company Address: Renub Research A -116B Sector -27 Noida - 201301 Uttar Pradesh India Phone: +91-120-4219-822, 4249-780

For free Sample copy report or to view any of our sample work please contact us at info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)

Follow Us
Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090 LinkedIn: http://www.linkedin.com/company/renub-research

Renub Research

Page 17 of 18

About Us
Renub Research
in international is a leading Market Research and Information Analysis Company with

centers at Noida India and Roswell USA. We have more than 7 years of experience especially Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others. Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research help make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in todays ultra-competitive markets.

Renub Research

Page 18 of 18